to investigate the role of intensive chemotherapy in chronic myelogenous leukemia ( cml ) , we treated 37 patients who had philadelphia-positive benign-phase disease with rubidazone 300 mg/m2/d 1 ( or daunorubicin 30 mg/m2/d x 4 ) , cytosine arabinoside 80 mg/m2/d x 10 , vincristine 2 mg/d 1 , and prednisone 100 mg/d x 5 ( roap 10 ) , every four weeks for a median of three cycles .
C0042679
vincristine
C0279394
roap